[342 Pages Report] The legionnaire disease testing market is projected to register a CAGR of 9% during the forecast period, up from US$ 292 Mn in 2022 to reach a valuation of US$ 819.5 Mn by 2032.
The legionnaire disease testing market is anticipated to show promising growth prospects during the forecast period as a result of growing competition. New competitors are offering a variety of options at reasonable pricing to fulfil the demand for legionnaire disease testing making it more accessible to customers in the global legionnaire disease testing market.
| Report Attribute | Details |
|---|---|
| Estimated Base Year Value (2021) | US$ 267 Million |
| Expected Market Value (2022) | US$ 292 Million |
| Anticipated Forecast Value (2032) | US$ 819.5 Million |
| Projected Growth Rate (2022-2032) | 9% CAGR |
Sales of legionnaire disease testing are expected to rise significantly. In addition to this, sales of legionnaire disease testing are rising on account for US$ 411.3 Mn by 2026. Increasing sales of legionnaire disease testing are also projected to contribute to the growth of the legionnaire disease testing market share.
Increasing public knowledge about effective illness detection and management has resulted from increased government programmes and financing. Furthermore, the worldwide legionnaire disease testing market is being driven by an increase in the need for better diagnostic methods as the prevalence rate rises.
The legionnaire illness testing market may expand as the adoption rate of legionnaire disease testing rises. The legionnaire disease testing market is also predicted to rise due to increased R&D initiatives for technology development for different illnesses.
The shortage of qualified specialists, on the other hand, is likely to stifle the legionnaire disease testing market expansion. Lack of resources and ignorance about infection are also predicted to stymie the sales of legionnaire disease testing market expansion.
Manufacturers in the legionnaire disease testing market get a big platform from which to serve the whole demand for legionnaire disease testing. The worldwide sales of legionnaire disease testing is seeing increased competition. With growing competition, new competitors are offering a variety of options at reasonable pricing, fulfilling the demand for legionnaire disease testing more accessible to customers.
Some of the key players present in the global legionnaire disease testing market are Beckman Coulter, Inc.; Albagaia Ltd.; Bio-Rad Laboratories, Inc.; Abbott Laboratories.; F. Hoffmann-La Roche AG; Thermo Fischer Scientific, Inc.; Becton, Dickinson and Company; Aquacert Ltd, BioMérieux SA; Idexx Laboratories Inc.; and others.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to the World Health Organization, 75-80% of the population is 50 years old or older, with 65-70% of the population being male. The male population is more susceptible to the demand for legionnaire disease testing than the female population.
Furthermore, the elderly are at a higher risk of legionnaire disease testing and are more likely to get infected. Globally, however, the advancement of innovative testing technologies is increasing. Increased knowledge of present and evolving technology is also helping to boost acceptance of the new testing method, which is projected to open up significant sales of legionnaire disease testing.
However, a scarcity of qualified healthcare providers, as well as a lack of knowledge of the condition and the inability to diagnose it at an early stage, may stymie the demand for legionnaire disease testing market expansion. Furthermore, the absence of improved healthcare facilities may limit the legionnaire disease testing market growth.
The sales of legionnaire disease testing market in Asia-Pacific are predicted to expand rapidly in the next years. This is owing to the existence of a huge population of people who are at high risk. In addition, a lack of knowledge on how to treat infectious diseases is adding to the region's growing population at risk.
The legionnaire disease testing market is predicted to increase rapidly as a result of this. Because of the region's excellent healthcare infrastructure and extensive research and development activities, the North American legionnaire disease testing market is likely to be the most prominent. Due to the availability of qualified researchers and a strong acceptance rate in the area, Europe will rank second in the sales of legionnaire disease testing market.
Due to a scarcity of qualified specialists in the region, the legionnaire disease testing market in Latin America is predicted to rise steadily. Due to a lack of facilities and public knowledge of legionnaire illness, the Middle East and Africa are likely to be the least profitable hence a decline in the demand for legionnaire disease testing.
Principal Consultant
The report consists of key players, contributing to the legionnaire disease testing market share. It also consists of organic and inorganic growth strategies adopted by market players to improve their market positions. This exclusive report analyzes the competitive landscape and legionnaire disease testing market share acquired by players to strengthen their market position.
Some of the key players present in the global legionnaire disease testing market are Beckman Coulter, Inc.; Albagaia Ltd.; Bio-Rad Laboratories, Inc.; Abbott Laboratories.; F. Hoffmann-La Roche AG; Thermo Fischer Scientific, Inc.; Becton, Dickinson and Company; Aquacert Ltd, BioMérieux SA; Idexx Laboratories Inc.; and others.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Report Attribute | Details |
|---|---|
| Growth rate | CAGR of 9% from 2022 to 2032 |
| Base year for estimation | 2021 |
| Historical data | 2015 - 2020 |
| Forecast period | 2022 - 2032 |
| Quantitative units | Revenue in USD Million and CAGR from 2022 to 2032 |
| Report coverage | Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis |
| Segments covered | Product type, diagnostic test, end user, region |
| Regional scope | North America; Western Europe, Eastern Europe, Middle East, Africa, ASEAN, South Asia, Rest of Asia, Australia and New Zealand |
| Country scope | U.S.; Canada; Mexico; Germany; U.K.; France; Italy; Spain; Russia; Belgium; Poland; Czech Republic; China; India; Japan; Australia; Brazil; Argentina; Colombia; Saudi Arabia; UAE; Iran; South Africa |
| Key companies profiled | Beckman Coulter, Inc.; Albagaia Ltd.; Bio-Rad Laboratories, Inc.; Abbott Laboratories.; F. Hoffmann-La Roche AG; Thermo Fischer Scientific, Inc.; Becton, Dickinson and Company; Aquacert Ltd, BioMérieux SA; Idexx Laboratories Inc.; and others |
| Customization scope | Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail of customized purchase options to meet your exact research needs. |
The legionnaire disease testing market is predicted to register a CAGR of 9% during the forecast period.
Key players holding substantial legionnaire disease testing market share include Beckman Coulter, Inc.; Albagaia Ltd.; Bio-Rad Laboratories, Inc.; Abbott Laboratories.; Aquacert Ltd, BioMérieux SA; Idexx Laboratories Inc.; and others
As per the analysis, the legionnaire disease testing market share is likely to be US$ 411.3 Mn by 2026.
Demand for legionnaire disease testing is likely to rise being driven by an increase in the need for better diagnostic methods as the prevalence rate rises.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Supply Chain Analysis
3.5.1. Supply Side Participants and their Roles
3.5.1.1. Producers
3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers)
3.5.1.3. Wholesalers and Distributors
3.5.2. Value Added and Value Created at Node in the Supply Chain
3.5.3. List of Raw Material Suppliers
3.5.4. List of Existing and Potential Buyer’s
3.6. Investment Feasibility Matrix
3.7. Value Chain Analysis
3.7.1. Profit Margin Analysis
3.7.2. Wholesalers and Distributors
3.7.3. Retailers
3.8. PESTLE and Porter’s Analysis
3.9. Regulatory Landscape
3.9.1. By Key Regions
3.9.2. By Key Countries
3.10. Regional Parent Market Outlook
3.11. Production and Consumption Statistics
3.12. Import and Export Statistics
4. Global Legionnaire Disease Testing Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Mn) & Volume (Units) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Legionnaire Disease Testing Market Analysis 2017-2021 and Forecast 2022-2032, By Product Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By Product Type, 2017-2021
5.3. Current and Future Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By Product Type, 2022-2032
5.3.1. Devices
5.3.2. Polymerase Chain Reaction System
5.3.3. Sequencer System
5.3.4. Test Kits
5.3.5. Assay Based Test Kits
5.3.6. Rapid Test Kits
5.4. Y-o-Y Growth Trend Analysis By Product Type, 2017-2021
5.5. Absolute $ Opportunity Analysis By Product Type, 2022-2032
6. Global Legionnaire Disease Testing Market Analysis 2017-2021 and Forecast 2022-2032, By Diagnostic Test
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By Diagnostic Test, 2017-2021
6.3. Current and Future Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By Diagnostic Test, 2022-2032
6.3.1. Culture Method
6.3.2. Urinary Antigen Test
6.3.3. Paired Serology
6.3.4. Direct Fluorescent Antibody Stain
6.3.5. Polymerase Chain Reaction
6.3.6. Combination Testing
6.4. Y-o-Y Growth Trend Analysis By Diagnostic Test, 2017-2021
6.5. Absolute $ Opportunity Analysis By Diagnostic Test, 2022-2032
7. Global Legionnaire Disease Testing Market Analysis 2017-2021 and Forecast 2022-2032, By End User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By End User, 2017-2021
7.3. Current and Future Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By End User, 2022-2032
7.3.1. Hospitals
7.3.2. Diagnostic Laboratories
7.3.3. Clinical Research Centers
7.3.4. Academic Institutes
7.3.5. Research Centers
7.3.6. Others
7.4. Y-o-Y Growth Trend Analysis By End User, 2017-2021
7.5. Absolute $ Opportunity Analysis By End User, 2022-2032
8. Global Legionnaire Disease Testing Market Analysis 2017-2021 and Forecast 2022-2032, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By Region, 2017-2021
8.3. Current Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By Region, 2022-2032
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. East Asia
8.3.5. South Asia & Pacific
8.3.6. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Legionnaire Disease Testing Market Analysis 2017-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
9.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. U.S.
9.2.1.2. Canada
9.2.2. By Product Type
9.2.3. By Diagnostic Test
9.2.4. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Product Type
9.3.3. By Diagnostic Test
9.3.4. By End User
9.4. Key Takeaways
10. Latin America Legionnaire Disease Testing Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Mexico
10.2.1.2. Brazil
10.2.1.3. Rest of Latin America
10.2.2. By Product Type
10.2.3. By Diagnostic Test
10.2.4. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Product Type
10.3.3. By Diagnostic Test
10.3.4. By End User
10.4. Key Takeaways
11. Europe Legionnaire Disease Testing Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. Italy
11.2.1.3. France
11.2.1.4. U.K.
11.2.1.5. Spain
11.2.1.6. BENELUX
11.2.1.7. Russia
11.2.1.8. Rest of Europe
11.2.2. By Product Type
11.2.3. By Diagnostic Test
11.2.4. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Product Type
11.3.3. By Diagnostic Test
11.3.4. By End User
11.4. Key Takeaways
12. East Asia Legionnaire Disease Testing Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.2. By Product Type
12.2.3. By Diagnostic Test
12.2.4. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Product Type
12.3.3. By Diagnostic Test
12.3.4. By End User
12.4. Key Takeaways
13. South Asia & Pacific Legionnaire Disease Testing Market Analysis 2017-2021 and Forecast 2022-2032, By Country
13.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
13.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
13.2.1. By Country
13.2.1.1. India
13.2.1.2. ASEAN
13.2.1.3. Australia and New Zealand
13.2.1.4. Rest of South Asia & Pacific
13.2.2. By Product Type
13.2.3. By Diagnostic Test
13.2.4. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Product Type
13.3.3. By Diagnostic Test
13.3.4. By End User
13.4. Key Takeaways
14. MEA Legionnaire Disease Testing Market Analysis 2017-2021 and Forecast 2022-2032, By Country
14.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
14.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. Turkey
14.2.1.3. South Africa
14.2.1.4. Rest of MEA
14.2.2. By Product Type
14.2.3. By Diagnostic Test
14.2.4. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Product Type
14.3.3. By Diagnostic Test
14.3.4. By End User
14.4. Key Takeaways
15. Key Countries Legionnaire Disease Testing Market Analysis
15.1. U.S.
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2021
15.1.2.1. By Product Type
15.1.2.2. By Diagnostic Test
15.1.2.3. By End User
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2021
15.2.2.1. By Product Type
15.2.2.2. By Diagnostic Test
15.2.2.3. By End User
15.3. Mexico
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2021
15.3.2.1. By Product Type
15.3.2.2. By Diagnostic Test
15.3.2.3. By End User
15.4. Brazil
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2021
15.4.2.1. By Product Type
15.4.2.2. By Diagnostic Test
15.4.2.3. By End User
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2021
15.5.2.1. By Product Type
15.5.2.2. By Diagnostic Test
15.5.2.3. By End User
15.6. Italy
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2021
15.6.2.1. By Product Type
15.6.2.2. By Diagnostic Test
15.6.2.3. By End User
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2021
15.7.2.1. By Product Type
15.7.2.2. By Diagnostic Test
15.7.2.3. By End User
15.8. U.K.
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2021
15.8.2.1. By Product Type
15.8.2.2. By Diagnostic Test
15.8.2.3. By End User
15.9. Spain
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2021
15.9.2.1. By Product Type
15.9.2.2. By Diagnostic Test
15.9.2.3. By End User
15.10. BENELUX
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2021
15.10.2.1. By Product Type
15.10.2.2. By Diagnostic Test
15.10.2.3. By End User
15.11. Russia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2021
15.11.2.1. By Product Type
15.11.2.2. By Diagnostic Test
15.11.2.3. By End User
15.12. China
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2021
15.12.2.1. By Product Type
15.12.2.2. By Diagnostic Test
15.12.2.3. By End User
15.13. Japan
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2021
15.13.2.1. By Product Type
15.13.2.2. By Diagnostic Test
15.13.2.3. By End User
15.14. South Korea
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2021
15.14.2.1. By Product Type
15.14.2.2. By Diagnostic Test
15.14.2.3. By End User
15.15. India
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2021
15.15.2.1. By Product Type
15.15.2.2. By Diagnostic Test
15.15.2.3. By End User
15.16. ASEAN
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2021
15.16.2.1. By Product Type
15.16.2.2. By Diagnostic Test
15.16.2.3. By End User
15.17. Australia and New Zealand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2021
15.17.2.1. By Product Type
15.17.2.2. By Diagnostic Test
15.17.2.3. By End User
15.18. GCC Countries
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2021
15.18.2.1. By Product Type
15.18.2.2. By Diagnostic Test
15.18.2.3. By End User
15.19. Turkey
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2021
15.19.2.1. By Product Type
15.19.2.2. By Diagnostic Test
15.19.2.3. By End User
15.20. South Africa
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2021
15.20.2.1. By Product Type
15.20.2.2. By Diagnostic Test
15.20.2.3. By End User
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Product Type
16.3.3. By Diagnostic Test
16.3.4. By End User
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Beckman Coulter, Inc.
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.1.5.2. Product Strategy
17.1.1.5.3. Channel Strategy
17.1.2. Bio-Rad Laboratories, Inc.
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.2.5.2. Product Strategy
17.1.2.5.3. Channel Strategy
17.1.3. Abbott Laboratories.
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.3.5.2. Product Strategy
17.1.3.5.3. Channel Strategy
17.1.4. F. Hoffmann-La Roche AG
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.4.5.2. Product Strategy
17.1.4.5.3. Channel Strategy
17.1.5. Thermo Fischer Scientific, Inc.
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.5.5.2. Product Strategy
17.1.5.5.3. Channel Strategy
17.1.6. Becton, Dickinson and Company
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.6.5.2. Product Strategy
17.1.6.5.3. Channel Strategy
17.1.7. Aquacert Ltd
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.7.5.2. Product Strategy
17.1.7.5.3. Channel Strategy
17.1.8. BioMérieux SA
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.8.5.2. Product Strategy
17.1.8.5.3. Channel Strategy
17.1.9. Idexx Laboratories Inc.
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.9.5.2. Product Strategy
17.1.9.5.3. Channel Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Legionnaire Disease Testing Market
